Biological Markers Predictive Of Anti-cancer Response To Epidermal Growth Factor Receptor Kinase Inhibitors

Abstract

The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by EGFR kinase inhibitors are also provided.


Claims
Owners (US)

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Feb 26, 2013
  • Application: Apr 13, 2007
    US US 78704407 A
  • Priority: Apr 13, 2007
    US US 78704407 A
  • Priority: Mar 16, 2006
    US US 37753006 A
  • Priority: Apr 15, 2005
    US US 67182105 P
  • Priority: Mar 16, 2005
    US US 66254505 P

Download Citation


Sign in to the Lens

Feedback